NU 578 Unit 1 Exam | ACTUAL EXAM | Advanced Pharmacology | University of South Alabama | 75 Questions & Verified Answers | Evidence-Based Prescribing | Pass Guaranteed - A+ Graded

Pass the NU 578 Unit 1 Advanced Pharmacology Exam on your first attempt with the most current actual exam resource available. This A+ Graded comprehensive study resource contains 75 Questions with Verified Answers fully aligned with the University of South Alabama NU 578 Advanced Pharmacology curriculum, covering foundational advanced pharmacology competencies and evidence-based prescribing principles essential for graduate-level nursing success. Designed to mirror the official NU 578 Unit 1 Examination format, this resource provides the most thorough preparation for advanced practice nursing students seeking to demonstrate mastery of pharmacokinetics, pharmacodynamics, pharmacotherapeutics, and clinical prescribing principles. Comprehensive content coverage includes: PHARMACOKINETICS Absorption: Bioavailability, first-pass effect, routes of administration (enteral: oral, sublingual, buccal, rectal; parenteral: IV, IM, SQ, intradermal, intrathecal; topical, transdermal, inhalation), factors affecting absorption (blood flow, pH, gastric emptying, food interactions, drug formulations), onset of action Distribution: Volume of distribution (Vd), protein binding (albumin, alpha-1 acid glycoprotein), factors affecting distribution (blood flow, tissue permeability, blood-brain barrier, placental barrier, body composition), drug reservoirs, redistribution Metabolism: Biotransformation, Phase I reactions (oxidation, reduction, hydrolysis, CYP450 enzyme system), Phase II reactions (conjugation: glucuronidation, acetylation, sulfation, methylation), first-pass metabolism, enzyme induction, enzyme inhibition, genetic polymorphisms (CYP2D6, CYP2C9, CYP2C19, CYP3A4), factors affecting metabolism (age, genetics, liver disease, drug interactions) Excretion: Renal excretion (glomerular filtration, tubular secretion, tubular reabsorption), half-life (t1/2), clearance, steady-state concentration, factors affecting excretion (renal function, age, urine pH, drug interactions), enterohepatic recirculation, non-renal elimination (biliary, pulmonary, sweat, breast milk) PHARMACODYNAMICS Mechanisms of Drug Action: Receptor theory (agonists: full, partial, inverse; antagonists: competitive, non-competitive, irreversible; allosteric modulators), dose-response relationships (graded dose-response, quantal dose-response, efficacy, potency, therapeutic index), receptor regulation (up-regulation, down-regulation, desensitization, tachyphylaxis), non-receptor mechanisms (physicochemical interactions, enzyme interactions, ion channels, transporters) Dose-Response Concepts: Median effective dose (ED50), median toxic dose (TD50), median lethal dose (LD50), therapeutic index (TI), therapeutic window, margin of safety, potency vs. efficacy, ceiling effect, maximal efficacy Drug Safety & Toxicity: Adverse drug reactions (ADRs): Type A (augmented, predictable, dose-dependent), Type B (bizarre, unpredictable, idiosyncratic), Type C (chronic), Type D (delayed), Type E (end of treatment), Type F (failure of therapy); medication errors prevention; adverse event reporting PHARMACOTHERAPEUTICS Principles of Drug Therapy: Indications, contraindications, precautions, black box warnings, off-label prescribing, medication reconciliation, prescription writing (DEA requirements, state regulations, electronic prescribing), medication adherence strategies Evidence-Based Prescribing: Clinical practice guidelines (ACC/AHA, ADA, GOLD, GINA, USPSTF), evidence hierarchy, systematic reviews, meta-analyses, randomized controlled trials, applying evidence to individual patients, shared decision-making, patient-centered prescribing Individualizing Drug Therapy: Patient-specific factors (age, weight, genetics, comorbidities, organ function, pregnancy/lactation), therapeutic drug monitoring (TDM), drug level interpretation (peak, trough, therapeutic range), dose adjustments DRUG INTERACTIONS & ADVERSE EFFECTS Drug-Drug Interactions: Pharmacokinetic interactions (absorption, distribution, metabolism, excretion), pharmacodynamic interactions (additive, synergistic, antagonistic), clinically significant interactions (CYP450 enzyme inducers/inhibitors, QT-prolonging drugs, serotonergic agents), drug interaction screening tools Drug-Food Interactions: Food effects on absorption, grapefruit juice interaction, tyramine and MAOIs, vitamin K and warfarin, calcium and tetracycline, alcohol interactions Drug-Herb Interactions: St. John's wort (CYP450 inducer), garlic, ginkgo, ginseng, echinacea, herbal supplement safety Adverse Drug Reaction Management: Recognition, assessment, documentation, reporting (FDA MedWatch), patient education, prevention strategies PHARMACOGENOMICS Genetic Variations in Drug Response: Pharmacogenomics principles, genetic polymorphisms affecting drug metabolism (CYP450 enzyme system), drug transporter variations (P-glycoprotein), receptor polymorphisms Clinically Relevant Pharmacogenetic Examples: Warfarin (CYP2C9, VKORC1), clopidogrel (CYP2C19), codeine and tramadol (CYP2D6, ultrarapid metabolizers, poor metabolizers), tamoxifen (CYP2D6), abacavir (HLA-B*5701), carbamazepine (HLA-B*1502), trastuzumab (HER2) Pharmacogenetic Testing: Indications, interpretation, clinical implementation, ethical considerations, patient counseling ACROSS THE LIFESPAN PHARMACOLOGY Pediatric Pharmacology: Developmental pharmacokinetics (gastric pH, immature liver enzymes, reduced renal function, increased body water), weight-based dosing (mg/kg), body surface area dosing, neonatal considerations (organ maturation, placental transfer, breastfeeding), FDA-approved pediatric indications, off-label prescribing in pediatrics, adverse drug reactions in children, medication administration considerations Geriatric Pharmacology: Age-related physiological changes (reduced renal function, decreased hepatic metabolism, increased body fat, decreased lean body mass, reduced albumin), polypharmacy, Beers Criteria (potentially inappropriate medications in older adults), START/STOPP criteria, medication safety in older adults, fall risk medications, anticholinergic burden, cognitive impairment considerations, deprescribing strategies Pregnancy Pharmacology: FDA pregnancy categories (historical and current Pregnancy and Lactation Labeling Rule - PLLR), placental transfer, teratogenicity risks by trimester (first trimester organogenesis, second/third trimester functional maturation), medication safety during pregnancy, pregnancy registries, treatment of chronic conditions in pregnancy Lactation Pharmacology: Lactation risk categories (L1-L5), medication excretion into breast milk, infant risk assessment, milk-to-plasma ratio, relative infant dose (RID), lactation safety resources (LactMed, Hale's Medications & Mothers' Milk), breastfeeding considerations Hepatic Impairment: Pharmacokinetic alterations in liver disease (reduced metabolism, decreased protein synthesis, altered distribution), Child-Pugh classification (Class A, B, C), dose adjustments for hepatic impairment, hepatotoxic medications, monitoring parameters Renal Impairment: Pharmacokinetic alterations in kidney disease (reduced excretion, altered distribution, accumulation of active metabolites), estimated glomerular filtration rate (eGFR) calculation (Cockcroft-Gault, MDRD, CKD-EPI), dose adjustments based on renal function, dialyzable medications, nephrotoxic medication management Obesity Pharmacology: Altered pharmacokinetics in obesity (increased volume of distribution, altered clearance), weight-based dosing considerations (ideal body weight, adjusted body weight, total body weight), drug distribution in adipose tissue, dosing recommendations for obese patients CLINICAL PRESCRIBING PRINCIPLES Rational Prescribing: Stepwise approach (identify problem, define diagnosis, consider patient factors, select therapy, initiate treatment, monitor outcomes, adjust therapy), shared decision-making, patient education, informed consent Prescription Writing: Components of a prescription (patient information, date, medication name, dose, route, frequency, duration, quantity, refills, signature), DEA controlled substance schedules (CII-V), electronic prescribing (e-prescribing), state-specific regulations, prescription monitoring programs (PMP) Medication Safety: High-alert medications, look-alike sound-alike medications, medication reconciliation, error reporting, patient safety strategies, adherence monitoring, therapeutic drug monitoring Ethical & Legal Considerations: Off-label prescribing, controlled substance prescribing, prescribing for self/family, professional boundaries, informed consent, confidentiality, cultural competence in prescribing KEY COMPETENCY INTEGRATION Clinical Reasoning & Decision-Making: Applying pharmacokinetic and pharmacodynamic principles to clinical scenarios, selecting appropriate drug therapy based on patient factors, interpreting drug levels, managing adverse effects, adjusting therapy based on response Evidence-Based Practice: Critically evaluating drug literature, applying clinical guidelines, understanding evidence hierarchy, incorporating patient preferences Interprofessional Collaboration: Communicating prescribing decisions, consulting with pharmacists, collaborating with healthcare team Each question includes verified answers with expert rationales explaining the "why" behind correct and incorrect answers, reinforcing pharmacokinetic principles, pharmacodynamic mechanisms, and clinical prescribing decisions essential for NU 578 success. Backed by our Pass Guarantee, this comprehensive NU 578 Unit 1 Exam resource delivers the ultimate preparation for University of South Alabama advanced pharmacology students. Download now for instant access and pass with confidence.